Expression of kallikrein 7 diminishes pancreatic cancer cell adhesion to vitronectin and enhances urokinase-type plasminogen activator receptor shedding

Pancreas

Volumn 37, Issue 4, 2008, Pages 399-404

  Ramani, Vishnu C ^a   Haun, Randy S ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cell adhesion; Extracellular matrix; Kallikrein 7; UPAR; Vitronectin

Indexed keywords

COLLAGEN TYPE 1; FIBRONECTIN; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; UROKINASE RECEPTOR; VITRONECTIN; VITRONECTIN RECEPTOR; KALLIKREIN; KLK7 PROTEIN, HUMAN; PLAUR PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ADHESION; CELL MOTILITY; CELL SURFACE; CONTROLLED STUDY; ENZYME RELEASE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; WESTERN BLOTTING; CULTURE MEDIUM; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

CELL ADHESION; CELL LINE, TUMOR; COLLAGEN TYPE I; CULTURE MEDIA, CONDITIONED; FIBRONECTINS; HUMANS; INTEGRIN ALPHAVBETA3; KALLIKREINS; PANCREATIC NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TRANSFECTION; VITRONECTIN;

EID: 58149172003     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31817f76f7     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Ellenrieder V, Adler G, Gress TM. Invasion and metastasis in pancreatic cancer. Ann Oncol. 1999;10(suppl 4):46-50.
3. Behrendt N, Ronne E, Ploug M, et al. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem. 1990;265:6453-6460.
4. Roldan AL, Cubellis MV, Masucci MT, et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 1990;9:467-474.
5. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des. 2003;9:1499-1528.
6. Hoyer-Hansen G, Behrendt N, Ploug M, et al. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 1997;420:79-85.
7. Kanse SM, Kost C, Wilhelm OG, et al. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res. 1996;224:344-353.
8. Wei Y, Waltz DA, Rao N, et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994;269: 32380-32388.
9. Ploug M, Ellis V, Dano K. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1- naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry. 1994;33: 8991-8997.
10. Behrendt N, Ploug M, Patthy L, et al. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem. 1991;266:7842-7847.
11. Madsen CD, Ferraris GM, Andolfo A, et al. uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol. 2007; 177:927-939.
12. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science. 1996;273:1551-1555.
13. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol. 1993;5:864-868.
14. Wilhelm OG, Wilhelm S, Escott GM, et al. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol. 1999;180:225-235.
15. Fazioli F, Resnati M, Sidenius N, et al. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997;16:7279-7286.
16. Andolfo A, English WR, Resnati M, et al. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb Haemost. 2002;88:298-306.
17. Resnati M, Guttinger M, Valcamonica S, et al. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996;15:1572-1582.
18. Stephens RW, Pedersen AN, Nielsen HJ, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem. 1997;43:1868-1876.
19. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 2004;24:13-39.
20. Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer. 1997;75:388-395.
21. Gao W, Wang Z, Bai X, et al. Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients. Thromb Res. 2001;102:25-31.
22. Johnson SK, Ramani VC, Hennings L, et al. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer. 2007;109:1811-1820.
23. Ramani VC, Haun RS. The extracellular matrix protein fibronectin is a substrate for kallikrein 7. Biochem Biophys Res Commun. 2008;369: 1169-1173.
24. Horton MA. The alpha v beta 3 integrin "vitronectin receptor." Int J Biochem Cell Biol. 1997;29:721-725.
25. Montuori N, Carriero MV, Salzano S, et al. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem. 2002;277:46932-46939.
26. Pedersen N, Schmitt M, Ronne E, et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest. 1993;92:2160-2167.
27. Holst-Hansen C, Hamers MJ, Johannessen BE, et al. Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies. Br J Cancer. 1999;81:203-211.
28. Blasi F, Stoppelli MP. Proteases and cancer invasion: from belief to certainty AACR meeting on proteases and protease inhibitors in cancer, Nyborg, Denmark, 14-18 June 1998. Biochim Biophys Acta. 1999;1423:R35-R44.
29. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis. 1992;10:145-155.
30. Monsky WL, Chen WT. Proteases of cell adhesion proteins in cancer. Semin Cancer Biol. 1993;4:251-258.
31. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res. 2004;2:257-280.
32. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 2004;4:876-890.
33. Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 2007;249:61-79.
34. Diamandis EP, Yousef GM, Luo LY, et al. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab. 2000;11:54-60.
35. Egelrud T. Purification and preliminary characterization of stratum corneum chymotryptic enzyme: a proteinase that may be involved in desquamation. J Invest Dermatol. 1993;101:200-204.
36. Egelrud T, Lundstrom A. A chymotrypsin-like proteinase that may be involved in desquamation in plantar stratum corneum. Arch Dermatol Res. 1991;283:108-112.
37. Ekholm E, Egelrud T. The expression of stratum corneum chymotryptic enzyme in human anagen hair follicles: further evidence for its involvement in desquamation-like processes. Br J Dermatol. 1998; 139:585-590.
38. Ronne E, Pappot H, Grondahl-Hansen J, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1995;89:576-581.
39. Montuori N, Visconte V, Rossi G, et al. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb Haemost. 2005;93:192-198.
40. Grondahl-Hansen J, Peters HA, van Putten WL, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res. 1995;1:1079-1087.
41. Mustjoki S, Sidenius N, Sier CF, et al. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res. 2000; 60:7126-7132.
42. Wahlberg K, Hoyer-Hansen G, Casslen B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res. 1998;58:3294-3298.
43. Pappot H, Hoyer-Hansen G, Ronne E, et al. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer. 1997;33:867-872.
44. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst. 1999;91:869-874.
45. Planque C, de Monte M, Guyetant S, et al. KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer. Biochem Biophys Res Commun. 2005;329: 1260-1266.
46. Talieri M, Diamandis EP, Gourgiotis D, et al. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb Haemost. 2004;91:180-186.
47. Shan SJ, Scorilas A, Katsaros D, et al. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. Clin Chem. 2006;52:1879-1886.
48. Tanimoto H, Underwood LJ, Shigemasa K, et al. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer. 1999;86: 2074-2082.
49. Tian X, Shigemasa K, Hirata E, et al. Expression of human kallikrein 7 (hK7/SCCE) and its inhibitor antileukoprotease (ALP/SLPI) in uterine endocervical glands and in cervical adenocarcinomas. Oncol Rep. 2004;12:1001-1006.
50. Wei Y, Yang X, Liu Q, et al. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol. 1999;144: 1285-1294.